A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Duchenne Muscular Dystrophy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Arkansas Children's Hospital, Little Rock, Arkansas, United States

    Contact: Study coordinator (Amber Kellogg) · aveerapandiyan@uams.edu · 501-364-3389
    Contact: Principal Investigator (Aravindhan Veerapandiyan, MD)
  • University of California, Los Angeles Medical Center, Los Angeles, California, United States

    Contact: Study coordinator (Ummi Qasim) · UQasim@mednet.ucla.edu · 310-825-3264
    Contact: Principal Investigator (Perry Shieh, MD, PhD)
  • University of California, Davis, Sacramento, California, United States

    Contact: Study coordinator (Neuromuscular Research Lab) · NMRL@ucdavis.edu · 916-734-5057
    Contact: Principal Investigator (Craig McDonald, MD)
  • University of California, San Diego, California, United States

    Contact: Study coordinator (Gabriella Penner) · gpenner@health.ucsd.edu · 858-382-3061
    Contact: Principal Investigator (Chamindra Laverty, MD)
  • Rare Disease Research, Atlanta, Georgia, United States

    Contact: Principal Investigator (Renata Shih, MD)
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

    Contact: Study coordinator (Alka Maheshwari) · amaheshwari@luriechildrens.org · 312-227-3813
    Contact: Study coordinator (Nancy Kuntz, MD)
  • Washington University in St. Louis, St Louis, Missouri, United States

    Contact: Study coordinator (Natalie Goedeker) · neuromusclepediatricresearch@wustl.edu · 314-362-4919
    Contact: Principal Investigator (Craig Zaidman, MD)
  • Nationwide Children's Hospital, Columbus, Ohio, United States

    Contact: Study coordinator (Destany McCain) · dbs001@nationwidechildrens.org · 614-722-6961
    Contact: Principal Investigator (Kevin Flanigan, MD)
  • Oregon Health and Sciences University, Portland, Oregon, United States

    Contact: Study coordinator (Beata Dyar) · dyar@ohsu.edu · 503-494-8216
    Contact: Principal Investigator (Erika Finanger, MD)
  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Brandt Parlanti) · parlantib@chop.edu · 215-850-7769
    Contact: Principal Investigator (John Brandsema, MD)
  • Children's Hospital of the King's Daughters, Norfolk, Virginia, United States

    Contact: Study coordinator (E.Ann Walker) · Proud.Research@CHKD.org · 757-668-6543
    Contact: Principal Investigator (Crystal Proud, MD)
  • Seattle Children's Hospital, Seattle, Washington, United States

    Contact: Study coordinator (Janaki O'Brien) · Janaki.OBrien@seattlechildrens.org · 206-987-1642
    Contact: Principal Investigator (Alicia Henriquez, MD)
  • The Hospital for Sick Children, Toronto, Ontario, Canada

    Contact: Study coordinator (Ana Stosic) · Ana.Stosic@SickKids.ca · 416-648-6831
    Contact: Principal Investigator (Hernan Gonorazky, MD)
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

    Contact: Study coordinator (Lorenzo Stivala) · lorenzo.stivala@policlinicogemelli.it · +39 063-015-6330
    Contact: Principal Investigator (Eugenio Mercuri, MD, PhD)
  • Great Ormond Street Hospital, London, United Kingdom

    Contact: Study coordinator (Lucinda Furtado) · Lucinda.furtado@gosh.nhs.uk · +44 (0)20 7762 6932
    Contact: Principal Investigator (Francesco Muntoni, MD)
Study leads
  • Solid Bio Clinical Trials

    Study Director

    Solid Biosciences